Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

@article{Deangelo2017InotuzumabOI,
  title={Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.},
  author={Daniel J. Deangelo and W. F. Keating Stock and Anthony S. Stein and Andrei R. Shustov and Michaela Liedtke and Charles A Schiffer and Erik R Vandendries and Katherine F. Liau and Revathi Ananthakrishnan and Joseph P. Boni and A. Douglas Laird and Luke Fostvedt and Hagop M Kantarjian and Anjali S. Advani},
  journal={Blood advances},
  year={2017},
  volume={1 15},
  pages={
          1167-1180
        }
}
This study evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of inotuzumab ozogamicin (InO) for CD22-positive relapsed/refractory acute lymphoblastic leukemia. In phase 1, patients received InO 1.2 (n = 3), 1.6 (n = 12), or 1.8 (n = 9) mg/m2 per cycle on days 1, 8, and 15 over a 28-day cycle (≤6 cycles). The recommended phase 2 dose (RP2D) was confirmed (expansion cohort; n = 13); safety and activity of InO were assessed in patients receiving the RP2D in phase 2… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 22 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Similar Papers

Loading similar papers…